1. Market Research
  2. > Back Pain – Pipeline Review, H1 2013

Back Pain – Pipeline Review, H1 2013

  • March 2013
  • -
  • Global Markets Direct
  • -
  • 97 pages

Back Pain – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Back Pain - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Back Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Back Pain. Back Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Back Pain.
- A review of the Back Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Back Pain pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Back Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Back Pain pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Back Pain - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Back Pain Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Back Pain 10
Back Pain Therapeutics under Development by Companies 12
Back Pain Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Pre-Clinical Stage Products 19
Comparative Analysis 19
Back Pain Therapeutics - Products under Development by Companies 20
Back Pain Therapeutics - Products under Investigation by Universities/Institutes 22
Companies Involved in Back Pain Therapeutics Development 23
DURECT Corporation 23
BioDelivery Sciences International, Inc. 24
Zogenix, Inc. 25
Eisai Co., Ltd. 26
Purdue Pharma L.P. 27
Teva Pharmaceutical Industries Limited 28
Collegium Pharmaceutical, Inc. 29
Mesoblast Ltd 30
Newron Pharmaceuticals S.p.A. 31
Teikoku Pharma USA, Inc. 32
Grunenthal GmbH 33
QRxPharma Limited 34
Sosei Co. Ltd. 35
Troikaa Pharmaceuticals Ltd. 36
Back Pain - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
hydrocodone bitartrate ER - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
(acetaminophen + hydrocodone bitartrate) CR - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
ABT-110 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
bupivacaine Trandermal - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
buprenorphine hydrochloride - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
(morphine sulfate + oxycodone) CR - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
Priralfinamide - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
cebranopadol - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
cycloserine - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
hydrocodone bitartrate ER - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
SD-726 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
oxycodone ER - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
Benztropine - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
TPH-023 - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
zoledronic acid - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
diclofenac sodium + eperisone - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
Mesenchymal Precursor Cells For Chronic Back Pain - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
REC-1100 - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
hydrocodone bitartrate - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
ATNC-05 - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
(diclofenac sodium + thiocolchicoside) - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
T-109 - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
AYX-2 - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
NuQu Cell-Based Therapy - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
AKR-202 - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
AKR-203 - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
Back Pain Therapeutics - Drug Profile Updates 76
Back Pain Therapeutics - Discontinued Products 87
Back Pain Therapeutics - Dormant Products 88
Back Pain - Product Development Milestones 90
Featured News and Press Releases 90
Oct 18, 2012: Collegium Pharma Announces Poster Presentation On Oxycodone DETERx At 2012 American Association Of Pharmaceutical Scientists Annual Meeting 90
Oct 18, 2012: Collegium Pharma Announces Poster Presentation On Oxycodone DETERx At 2012 American Association Of Pharmaceutical Scientists Annual Meeting 90
Aug 29, 2012: Collegium Pharma Initiates Enrollment In Phase III Efficacy Study Of Oxycodone DETERx In Subjects With Moderate To Severe Chronic Lower Back Pain 91
Jul 23, 2012: Mitsubishi Tanabe Pharma Announces Launch Of Tranquilizer Depas Tablets 0.25Mg 91
Jul 06, 2012: Lilly Obtains Six Months US Pediatric Exclusivity For Cymbalta 92
Apr 17, 2012: Mesoblast Announces Intervertebral Disc Repair Phase II Trial Update 92
Sep 26, 2011: Collegium Pharmaceutical Announces Successful Type A Meeting With FDA For Tamper-Resistant, Extended Release Opioid 93
Apr 29, 2011: Lilly Receives Health Canada Approval For Cymbalta For Chronic Low Back Pain 93
Apr 11, 2011: DURECT Announces ELADUR Phase II Study Results In Chronic Low Back Pain 94
Nov 30, 2010: Zogenix Completes Enrollment In ZX002 Phase III 12-Month Safety Study 94
Appendix 96
Methodology 96
Coverage 96
Secondary Research 96
Primary Research 96
Expert Panel Validation 96
Contact Us 97
Disclaimer 97



List of Tables

Number of Products Under Development for Back Pain, H1 2013 10
Products under Development for Back Pain - Comparative Analysis, H1 2013 11
Number of Products under Development by Companies, H1 2013 13
Number of Products under Development by Companies, H1 2013 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2013 15
Comparative Analysis by Late Stage Development, H1 2013 16
Comparative Analysis by Mid Clinical Stage Development, H1 2013 17
Comparative Analysis by Early Clinical Stage Development, H1 2013 18
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 19
Products under Development by Companies, H1 2013 20
Products under Development by Companies, H1 2013 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2013 22
DURECT Corporation, H1 2013 23
BioDelivery Sciences International, Inc., H1 2013 24
Zogenix, Inc., H1 2013 25
Eisai Co., Ltd., H1 2013 26
Purdue Pharma L.P., H1 2013 27
Teva Pharmaceutical Industries Limited, H1 2013 28
Collegium Pharmaceutical, Inc., H1 2013 29
Mesoblast Ltd, H1 2013 30
Newron Pharmaceuticals S.p.A., H1 2013 31
Teikoku Pharma USA, Inc., H1 2013 32
Grunenthal GmbH, H1 2013 33
QRxPharma Limited, H1 2013 34
Sosei Co. Ltd., H1 2013 35
Troikaa Pharmaceuticals Ltd., H1 2013 36
Assessment by Monotherapy Products, H1 2013 37
Assessment by Combination Products, H1 2013 38
Assessment by Stage and Route of Administration, H1 2013 40
Assessment by Stage and Molecule Type, H1 2013 42
Back Pain Therapeutics - Drug Profile Updates 76
Back Pain Therapeutics - Discontinued Products 87
Back Pain Therapeutics - Dormant Products 88
Back Pain Therapeutics - Dormant Products (Contd..1) 89



List of Figures

Number of Products under Development for Back Pain, H1 2013 10
Products under Development for Back Pain - Comparative Analysis, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 15
Late Stage Products, H1 2013 16
Mid Clinical Stage Products, H1 2013 17
Early Clinical Stage Products, H1 2013 18
Pre-Clinical Stage Products, H1 2013 19
Assessment by Monotherapy Products, H1 2013 37
Assessment by Combination Products, H1 2013 38
Assessment by Route of Administration, H1 2013 39
Assessment by Stage and Route of Administration, H1 2013 40
Assessment by Molecule Type, H1 2013 41
Assessment by Stage and Molecule Type, H1 2013 42

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.